Public Employees Retirement Association of Colorado cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,926 shares of the specialty pharmaceutical company’s stock after selling 412 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Jazz Pharmaceuticals PLC were worth $1,449,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in JAZZ. Albion Financial Group UT raised its position in shares of Jazz Pharmaceuticals PLC by 0.5% in the second quarter. Albion Financial Group UT now owns 2,783 shares of the specialty pharmaceutical company’s stock valued at $393,000 after buying an additional 15 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Jazz Pharmaceuticals PLC by 0.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,282 shares of the specialty pharmaceutical company’s stock valued at $322,000 after buying an additional 17 shares in the last quarter. First Allied Advisory Services Inc. raised its position in shares of Jazz Pharmaceuticals PLC by 0.3% in the second quarter. First Allied Advisory Services Inc. now owns 7,826 shares of the specialty pharmaceutical company’s stock valued at $1,106,000 after buying an additional 22 shares in the last quarter. OLD National Bancorp IN raised its position in shares of Jazz Pharmaceuticals PLC by 1.5% in the second quarter. OLD National Bancorp IN now owns 1,949 shares of the specialty pharmaceutical company’s stock valued at $275,000 after buying an additional 29 shares in the last quarter. Finally, Ranger Investment Management L.P. raised its position in shares of Jazz Pharmaceuticals PLC by 0.3% in the second quarter. Ranger Investment Management L.P. now owns 17,740 shares of the specialty pharmaceutical company’s stock valued at $2,507,000 after buying an additional 60 shares in the last quarter. Institutional investors and hedge funds own 89.70% of the company’s stock.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 2.04% during midday trading on Tuesday, hitting $105.84. 643,138 shares of the stock traded hands. The stock has a market capitalization of $6.34 billion, a P/E ratio of 18.51 and a beta of 1.35. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $160.00. The firm has a 50-day moving average price of $113.78 and a 200-day moving average price of $132.31.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 EPS for the quarter, missing the consensus estimate of $2.61 by $0.04. Jazz Pharmaceuticals PLC had a return on equity of 30.50% and a net margin of 24.81%. The business had revenue of $374 million for the quarter, compared to analyst estimates of $389.34 million. During the same quarter in the prior year, the business earned $2.52 earnings per share. The firm’s quarterly revenue was up 9.8% on a year-over-year basis. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post $9.96 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is the propert of of Daily Political. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at http://www.dailypolitical.com/2016/11/29/public-employees-retirement-association-of-colorado-has-1449000-position-in-jazz-pharmaceuticals-plc-jazz.html.

Several brokerages recently weighed in on JAZZ. Deutsche Bank AG restated a “buy” rating and issued a $158.00 price objective (up from $155.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 11th. Mizuho lowered their target price on shares of Jazz Pharmaceuticals PLC from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. Barclays PLC reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 10th. Leerink Swann reaffirmed a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, August 11th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $195.00 target price (down previously from $196.00) on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, August 11th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $179.91.

In other news, SVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $126.17, for a total value of $25,234.00. Following the transaction, the senior vice president now owns 17,325 shares in the company, valued at approximately $2,185,895.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kenneth W. O’keefe purchased 2,000 shares of the company’s stock in a transaction dated Monday, November 14th. The stock was purchased at an average price of $113.84 per share, for a total transaction of $227,680.00. Following the transaction, the director now directly owns 12,107 shares in the company, valued at approximately $1,378,260.88. The disclosure for this purchase can be found here. Corporate insiders own 3.90% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.